Medicinova (MNOV) vs vTv Therapeutics (VTVT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Medicinova (MNOV) has outperformed vTv Therapeutics (VTVT) over the past year, losing 8.4% versus a loss of 47.5%. Over five years, MNOV leads with a -59.3% price change compared with -71.1% for VTVT. Medicinova is the larger company by market cap ($67.1 million vs $62.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MNOV | VTVT |
|---|---|---|
| Share price | $1.31 | $15.51 |
| Market cap | $67.11M | $62.22M |
| 1-day change | +3.15% | -5.20% |
| YTD return | 0.00% | -61.22% |
| 1-year return | -8.39% | -47.53% |
| 5-year return | -59.32% | -71.06% |
| EPS (TTM) | $-0.21 | $-0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $409.66K | $0 |
| Revenue growth (YoY) | — | -100.00% |
| Net income (latest FY) | $-12.00M | $-26.97M |
| Operating margin | -3242.47% | — |
| Net margin | -2928.78% | — |
| 52-week high | $3.90 | $44.00 |
| 52-week low | $1.22 | $15.47 |
| Distance from 52-week high | -66.41% | -64.75% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +529.77% | +261.06% |
| Average volume | 334.96K | 33.07K |
| Shares outstanding | 51.23M | 4.01M |
| Employees | 6 | 26 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MNOV has outperformed VTVT by 39.1 percentage points over the past year.
About Medicinova
MNOV stock →MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About vTv Therapeutics
VTVT stock →vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
MNOV vs VTVT FAQ
Which is bigger, Medicinova or vTv Therapeutics?
Medicinova (MNOV) is larger, with a market capitalization of $67.11M compared with $62.22M for vTv Therapeutics (VTVT).
Which stock has performed better over the past year, MNOV or VTVT?
MNOV returned -8.39% over the past 12 months, compared with -47.53% for VTVT (price return, excluding dividends). Past performance does not predict future results.
Are Medicinova and vTv Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.